3-year Immunogenicity Evaluation of Quadrivalent HPV Vaccine in China
NCT01427777 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2011-09-02
Summary
The thirty-six-month immunogenicity evaluation of Quadrivalent HPV (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) Vaccine in Chinese female subjects aged 9 to 45 years and male subjects aged 9 to 15 years.
Conditions
- Anogenital Human Papilloma Virus Infection
Sponsors & Collaborators
-
Guangxi Center for Disease Control and Prevention
lead OTHER_GOV
Principal Investigators
-
Rongcheng Li, MD · Guangxi CDC
Eligibility
- Min Age
- 9 Years
- Max Age
- 45 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2011-09-30
- Completion
- 2012-06-30
Countries
- China
Study Locations
More Related Trials
-
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
NCT05371353 ·Status: RECRUITING
-
A Randomized, Blinded, Placebo-controlled Phase I Clinical Trial Evaluating the Safety and Preliminary Immunogenicity of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
NCT04083196 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT03676101 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT04422366 ·Status: RECRUITING ·Phase: PHASE3
-
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT04425291 ·Status: COMPLETED ·Phase: PHASE3
-
Immunobridging Study of 9- Valent Human Papillomavirus (9vHPV) Vaccine (V503) in Chinese Females 9 to 45 Years of Age (V503-024)
NCT03903562 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
NCT05262010 ·Status: RECRUITING ·Phase: PHASE3
-
Immunogenicity and Safety of Sequential 2vHPV-9vHPV Vaccination in Girls Aged 9-14 Years
NCT07281677 ·Status: RECRUITING ·Phase: PHASE4
-
Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 Vaccine in Healthy Females
NCT02740790 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Quadrivalent Human Papillomavirus Vaccine (V501) in Chinese Girls Aged 9-19 Years and Young Women Aged 20-26 Years (V501-213)
NCT03493542 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
NCT05372016 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
NCT04537156 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine
NCT03900572 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)
NCT04436133 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Immunogenicity Study of Human Papilloma Virus Vaccine in Women Aged 9 to 30 and Men Aged 9 to 17
NCT02888418 ·Status: UNKNOWN ·Phase: PHASE1
-
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
NCT05056402 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Long-term Follow-up of Bivalent Human Papillomavirus (HPV) Vaccine Study in Women
NCT06776055 ·Status: ACTIVE_NOT_RECRUITING
-
Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine
NCT01263327 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase III Study of Human Papillomavirus (HPV)-16/18 Vaccine.
NCT02733068 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluate the Immunogenicity & Safety of GSK Biologicals' HPV Vaccine in Female Subjects Aged 10-14 Years
NCT00290277 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
NCT05694728 ·Status: COMPLETED ·Phase: PHASE2
-
An Immunogenicity and Safety Study of Gardasil® in Chinese Subjects (V501-030)(COMPLETED)
NCT00496626 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
NCT05662020 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
NCT04895020 ·Status: RECRUITING ·Phase: PHASE3
-
Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
NCT03813940 ·Status: COMPLETED ·Phase: PHASE1